Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2000 June; 1(2): 1–7.
Published online 2015 February 19. doi:  10.1208/pt010207
PMCID: PMC2784819

Kinetics of pramlintide degradation in aqueous solution as a function of temperature and pH


The stability of the 37-amino acid peptide pramlintide, in aqueous solution, was studied as a function of pH and temperature. Samples of pramlintide formulated as a parenteral product were exposed to elevated temperatures and to realistic storage conditions for as long as 30 months. Pramlintide degradation was monitored by three high-performance liquid chromatography (HPLC) methods: a reversedphase (RP-HPLC) and a strong-cation exchange (SCX-HPLC) method for percentage purity determination by area normalization, plus a second RP-HPLC method for potency determinationversus external standards. The pH-rate profile for pramlintide shows increasing degradation rate constants with increasing pH over the range pH=3.5 to 5.0. The Arrhenius expression for pramlintide degradation at pH=4.0 over the temperature range 5°C to 50°C is In(k0)=37.39−21.900/RT, where k0 is the zero-order rate constant (in %/mo) for pramlintide degradation. The pramlintide parenteral product formulated at pH=4.0 is extremely stable, with percentage purity and percentage potency loss of only approximately 2% over 30 months at 5°C. The formulated pramlintide drug product has acceptable shelf life for long-term storage at 5°C and up to a 30-day patient use when stored at ambient temperature.

Keywords: Pramlintide, Hydrolysis, pH, Arrhenius, RP-HPLC, SCX-HPLC, Orthogonal Separation

Full Text

The Full Text of this article is available as a PDF (113K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Young A, Pittner R, Gedulin B, Vine W, Rink T. Amylin. Regulation of carbohydrate metabolism. Biochem Soc Trans. 1995;23:325–331. [PubMed]
2. Scherbaum WA. The role of amylin in the physiology of glycemic control. Experimental and Clinical Endocrinol and Diabetes. 1998;106(2):97–102. doi: 10.1055/s-0029-1211958. [PubMed] [Cross Ref]
3. Amiel S. Amylin and diabetes. Lancet. 1993;341:1249–1250. doi: 10.1016/0140-6736(93)91153-D. [PubMed] [Cross Ref]
4. Janes S, Gaeta L, Beaumont K, Beeley K, Rink T. The selection of pramlintide for clinical evaluation. Diabetes. 1996;45(Suppl 2):235A–235A.
5. Thompson RG, Gottlieb A, Organ K, Kolterman OG. Pramlintide, a human amylin analog reduced post-prandial plasma glucose. insulin and c-peptide concentrations in patients with type II diabetes. Diabetic Medicine. 1997;14(7):547–555. doi: 10.1002/(SICI)1096-9136(199707)14:7<547::AID-DIA390>3.0.CO;2-U. [PubMed] [Cross Ref]
6. Thompson RG, Peterson J, Gottlieb A, Mullane J. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multi-center trial. Diabetes. 1997;46(4):632–636. doi: 10.2337/diabetes.46.4.632. [PubMed] [Cross Ref]
7. Brower V. Amylin's pramlintide best of bad bunch of diabetes drugs. Nature Biotechnol. 1997;15(10):935–935. doi: 10.1038/nbt1097-935. [PubMed] [Cross Ref]
8. Hekman C, Demond W, Dixit T, et al. Isolation and identification of peptide degradation products of heat stressed pramlintide injection drug product. Pharm Res. 1998;15:650–659. doi: 10.1023/A:1011934829263. [PubMed] [Cross Ref]
9. Demond W, Lokensgard D, Kelley P, Herman K, Weilersbacher G, Kenley R. Orthogonal HPLC methods for quantitating related substances and degradation products of pramlintide. AAPS PharmSciTech. 2000;1(1):6–6. doi: 10.1208/pt010106. [PMC free article] [PubMed] [Cross Ref]
10. Ahern TJ, Manning MC, editors. Stability of Protein Pharmaceuticals. Part A. Chemical and Physical Pathways of Protein Degradation. New York, NY: Plenum Press; 1992.
11. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6:903–917. doi: 10.1023/A:1015929109894. [PubMed] [Cross Ref]
12. Patel K, Borchardt RT. Chemical pathways of degradation III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides. Pharm Res. 1990;7:787–793. doi: 10.1023/A:1015999012852. [PubMed] [Cross Ref]
13. Capasso S, Mazzarella L, Zagari A. Deamidation via cyclic imide of asparaginyl peptides: dependence on salts. buffers, and organic solvents. Peptide Res. 1991;4:234–241. [PubMed]
14. Robinson AB, Scotchler JW, McKerrow JM. Rates of nonenzymatic deamidation of glutaminyl and asparaginyl residues in pentapeptides. J Am Chem Soc. 1973;85:8156–8159. doi: 10.1021/ja00805a032. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists